allyl-(4-chloro-5-fluoro-2-nitro-benzyl)-methyl-amine | 855995-86-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: allyl-(4-chloro-5-fluoro-2-nitro-benzyl)-methyl-amine
• 英文别名: N-[(4-chloro-5-fluoro-2-nitrophenyl)methyl]-N-methylprop-2-en-1-amine
• CAS: 855995-86-7
• 化学式: C₁₁H₁₂ClFN₂O₂
• 分子量: 258.68
• InChiKey: BRYSNUIPGCSMRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  49.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  allyl-(4-chloro-5-fluoro-2-nitro-benzyl)-methyl-amine 在 铁粉 、 氯化铵 作用下， 以 水 、 甲苯 为溶剂， 生成 2-[(allylmethyl-amino)-methyl]-5-chloro-4-fluoro-phenylamine
  参考文献：
  名称：

  [EN] PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI- PROLIFERATIVE AGENTS
  [FR] ANTI-PROLIFERANTS A BASE DE DERIVES PYRIDO- ET PYRIMIDOPYRIMIDINE

  摘要：

  本发明涉及公式(I)的化合物，其N-氧化物形式，药学上可接受的加合盐及其立体化异构形式，其中a1-a2=a3-a4代表从N-CH=CH-CH，N-CH N-CH或CH-CH=N-CH中选择的二价基团；Z代表NH；Y代表-C3-9烷基-，-Cl-5烷基-NR13-Cl-5烷基-，-C1-6烷基-NH-CO-或-CO-NH -C1-6烷基-；X1代表-O-或-NR11-；X2代表-C1-2烷基-，-O-C1-2烷基，-O-或-O-CH2-；R1代表氢或卤素；R2代表氢，氰基，卤素，羟基甲酰-Cl-4烷氧基甲酰-，Het16-羰基或Ar5；R3代表氢；R4代表羟基，C1-4烷氧基-，Ar4-C1-4烷氧基或R4代表Cl-4烷氧基，其中一个或可能两个或更多取代基选择自C1-4烷氧基-或Het2-；R11代表氢；R12代表氢，Cl-4烷基-或Cl-4烷氧基甲酰-；R13代表Het14-Cl-4烷基，特别是吗啡啶基-Cl-4烷基；Het2代表选择自吗啡啶基或哌啶基的杂环，可选地取代为C1-4烷基-，最好是甲基；Het14代表吗啡啶基；Het16代表选择自吗啡啶基或吡咯啉基的杂环；Ar4代表苯基；Ar5代表苯基，可选地取代为氰基。

  公开号：

  WO2005058913A1
• 作为产物：
  描述：

  在 sodium triacetylborohydride 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 allyl-(4-chloro-5-fluoro-2-nitro-benzyl)-methyl-amine
  参考文献：
  名称：

  [EN] PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI- PROLIFERATIVE AGENTS
  [FR] ANTI-PROLIFERANTS A BASE DE DERIVES PYRIDO- ET PYRIMIDOPYRIMIDINE

  摘要：

  本发明涉及公式(I)的化合物，其N-氧化物形式，药学上可接受的加合盐及其立体化异构形式，其中a1-a2=a3-a4代表从N-CH=CH-CH，N-CH N-CH或CH-CH=N-CH中选择的二价基团；Z代表NH；Y代表-C3-9烷基-，-Cl-5烷基-NR13-Cl-5烷基-，-C1-6烷基-NH-CO-或-CO-NH -C1-6烷基-；X1代表-O-或-NR11-；X2代表-C1-2烷基-，-O-C1-2烷基，-O-或-O-CH2-；R1代表氢或卤素；R2代表氢，氰基，卤素，羟基甲酰-Cl-4烷氧基甲酰-，Het16-羰基或Ar5；R3代表氢；R4代表羟基，C1-4烷氧基-，Ar4-C1-4烷氧基或R4代表Cl-4烷氧基，其中一个或可能两个或更多取代基选择自C1-4烷氧基-或Het2-；R11代表氢；R12代表氢，Cl-4烷基-或Cl-4烷氧基甲酰-；R13代表Het14-Cl-4烷基，特别是吗啡啶基-Cl-4烷基；Het2代表选择自吗啡啶基或哌啶基的杂环，可选地取代为C1-4烷基-，最好是甲基；Het14代表吗啡啶基；Het16代表选择自吗啡啶基或吡咯啉基的杂环；Ar4代表苯基；Ar5代表苯基，可选地取代为氰基。

  公开号：

  WO2005058913A1

文献信息

• [EN] 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY<br/>[FR] DERIVES DE 3-CYANO-QUINOLINE A ACTIVITE ANTIPROLIFERATIVE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005058318A1

  公开（公告）日：2005-06-30

  The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof. Compounds of formula (I) inhibit tyrosine kinase enzymes.

  本发明涉及式(I)的化合物，其N-氧化物形式，药用可接受的加合盐以及其立体化异构体形式。式(I)的化合物抑制酪氨酸激酶酶。
• PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1697384B1

  公开（公告）日：2008-04-02
• Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents
  申请人：Freyne Jean Edgard Eddy

  公开号：US20070078132A1

  公开（公告）日：2007-04-05

  The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein a 1 -a 2 =a 3 -a 4 represents a divalent radical selected from N—CH═CH—CH, N—CH═N—CH or CH—CH═N—CH; Z represents NH; Y represents —C 3-9 alkyl-, —C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-6 alkyl-NH—CO— or —CO—NH—C 1-6 alkyl-; X 1 represents —O— or —NR 11 —; X 2 represents —C 1-2 alkyl-, —O—C 1-2 alkyl, —O— or —O—CH 2 —; R 1 represents hydrogen or halo; R 2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C 1-4 alkyloxycarbonyl-, Het 16 -carbonyl- or Ar 5 ; R 3 represents hydrogen; R 4 represents hydroxy, C 1-4 alkyloxy-, Ar 4 —C 1-4 alkyloxy or R 4 represents C 1-4 alkyloxy substituted with one or where possible two or more substituents selected from C 1-4 alkyloxy- or Het 2 -; R 11 represents hydrogen; R 12 represents hydrogen, C 1-4 alkyl- or C 1-4 alkyl-oxy-carbonyl-; R 13 represents Het 14 -C 1-4 alkyl, in particular morpholinyl-C 1-4 alkyl; Het 2 represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C 1-4 alkyl-, preferably methyl; Het 14 represents morpholinyl; Het 16 represents a heterocycle selected from morpholinyl or pyrrolidinyl; Ar 4 represents phenyl; Ar 5 represents phenyl optionally substituted with cyano.
• 3-Cyano-Quinoline Derivatives With Antiproliferative Activity
  申请人：Freyne Eddy Jean Edgard

  公开号：US20080139601A1

  公开（公告）日：2008-06-12

  The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents NH; Y represents —C 3-9 alkyl-, —C 1-5 alkyl-NR 12 —C 1-5 alkyl-, —C 1-6 alkyl-NH—CO— or —CO—NH—C 1-6 alkyl-; X 1 represents —O—; X 2 represents a direct bond, —NR 11 —C 1-2 alkyl-, —NR 11 —CH 2 —, —C 1-2 alkyl-, —O—C 1-2 alkyl, —O— or —O—CH 2 —; R 1 represents hydrogen or halo; R 2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C 1-4 alkyloxycarbonyl-, Het 16 -carbonyl- or Ar 5 ; R 3 represents hydrogen, hydroxy, C 1-4 alkyloxy-, Ar 4 —C 1-4 alkyloxy or R 3 represents C 1-4 alkyloxy substituted with one or where possible two or more substituents selected from C 1-4 alkyloxy- or Het 2 -; R 10 represents hydrogen; R 11 represents hydrogen, C 1-4 alkyl- or C 1-4 alkyl-oxy-carbonyl-; R 12 represents Het 14 -C 1-4 alkyl, in particular morpholinyl-C 1-4 alkyl; Het 2 represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C 1-4 alkyl-, preferably methyl; Het 14 represents morpholinyl; Het 16 represents a heterocycle selected from morpholinyl or pyrrolidinyl; Ar 4 represents phenyl; Ar 5 represents phenyl optionally substituted with cyano.
• 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY
  申请人：FREYNE Eddy Jean Edgard

  公开号：US20100069424A1

  公开（公告）日：2010-03-18

  The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents NH; Y represents —C 3-9 alkyl-, —C 1-5 alkyl-NR 12 —C 1-5 alkyl-, —C 1-6 alkyl-NH—CO— or —CO—NH—C 1-6 alkyl-; X 1 represents —O—; X 2 represents a direct bond, —NR 11 —C 1-2 alkyl-, —NR 11 —CH 2 —, —C 1-2 alkyl-, —O—C 1-2 alkyl, —O— or —O—CH 2 —; R 1 represents hydrogen or halo; R 2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C 1-4 alkyloxycarbonyl-, Het 16 -carbonyl- or Ar 5 ; R 3 represents hydrogen, hydroxy, C 1-4 alkyloxy-, Ar 4 —C 1-4 alkyloxy or R 3 represents C 1-4 alkyloxy substituted with one or where possible two or more substituents selected from C 1-4 alkyloxy- or Het 2 -; R 10 represents hydrogen; R 11 represents hydrogen, C 1-4 alkyl- or C 1-4 alkyl-oxy-carbonyl-; R 12 represents Het 14 -C 1-4 alkyl, in particular morpholinyl-C 1-4 alkyl; Het 2 represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C 1-4 alkyl-, preferably methyl; Het 14 represents morpholinyl; Het 16 represents a heterocycle selected from morpholinyl or pyrrolidinyl; Ar 4 represents phenyl; Ar 5 represents phenyl optionally substituted with cyano.